A clinically validated innovative technology
Following years of intensive research and development, Remedee Labs has developed a breakthrough approach to pain relief, by stimulating a person’s own endorphins.
In light of significant interest from the medical community to find new ways to relieve pain safely and effectively, the Remedee Labs endorphin-stimulation solution is being tested in multiple clinical trials.
Today, its effectiveness has been demonstrated in osteoarthritis and fibromyalgia
FIBROMYLAGIa
1st CE marked medical device approved for the treatment of fibromyalgia in Europe
The Remedee Labs solution, which uses the first millimeter wave endorphin stimulator wristband, is the first medical device clinically validated and certified in Europe to provide symptom relief for fibromyalgia.
La solution de Remedee Labs est le premier dispositif médical validé cliniquement et certifié en Europe pour soulager les symptômes de la fibromyalgie L’obtention du statut de dispositif médical a été appuyée par l’étude clinique FIBREPIK. Les résultats ont été présentés en novembre 2023 au congrès de l’American College of Rheumathology (ACR) à San Diego (USA).
Les résultats ont montré qu’une utilisation trois fois par jour (30 minutes) du bracelet Remedee™ avait permis une nette amélioration de la qualité de vie des participants, avec une diminution significative de la douleur, de la fatigue générale et physique, de l’anxiété et de la dépression ainsi qu’une amélioration de la qualité du sommeil.
Significant improvement in quality of life.(FIQ)
The study results showed a clear improvement in patients’ quality of life. 55.1% of participants reduced their Fibromyalgia Impact Questionnaire (FIQ) score after 3 months of use. That figure reached 62.3% for participants who followed the clinical protocol for use of the solution (per protocol results).
An improvement
in health status (PGIC)
hôpitaux impliquées
OSTEOARTHRITIS
A new approach to relieve osteoarthritis
Remedee Labs’ innovative, non-invasive technology has been clinically tested on 60 volunteers with peripheral osteoarthritis (ankle, knee, hip, shoulder, elbow, digital) by the Grenoble-Alpes University Hospital.
The results of the study showed that regular use (1 to 3 times a day) of the endorphin stimulator for 3 months resulted in a significant reduction in pain (VAS) in osteoarthritis patients.
The authors of the study also noted an overall improvement in the quality of life (EQ5D-5L) and sleep quality (VAS) of the patients included. No adverse events considered severe were observed.
Une amélioration du sommeil
et de la qualité de vie
Les résultats de l’étude ont montré une amélioration de la qualité du sommeil et plus globalement de la qualité de vie des patients inclus.
Une diminution de
la douleur à 3 mois
Echelle EVA
